Statements (25)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:administered_by |
oral tablet
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:atccode |
L04 AX03
|
| gptkbp:bioavailability |
60% to 80%
|
| gptkbp:chemical_formula |
C19 H17 N3 O3
|
| gptkbp:clinical_trial |
Phase 3
|
| gptkbp:dosage_form |
gptkb:tablet
gptkb:capsule |
| gptkbp:effective_date |
gptkb:2014
|
| https://www.w3.org/2000/01/rdf-schema#label |
Esbriet
|
| gptkbp:ingredients |
gptkb:pirfenidone
|
| gptkbp:manufacturer |
gptkb:Genentech
|
| gptkbp:marketed_as |
gptkb:European_Union
gptkb:United_States |
| gptkbp:mechanism_of_action |
anti-fibrotic agent
|
| gptkbp:side_effect |
fatigue
nausea diarrhea rash liver problems |
| gptkbp:trade |
gptkb:Esbriet
|
| gptkbp:used_for |
gptkb:idiopathic_pulmonary_fibrosis
|
| gptkbp:bfsParent |
gptkb:Hoffmann-La_Roche
|
| gptkbp:bfsLayer |
6
|